Treatment of Angina Pectoris Associated with Coronary Microvascular Dysfunction.
Τίτλος | Treatment of Angina Pectoris Associated with Coronary Microvascular Dysfunction. |
Publication Type | Journal Article |
Year of Publication | 2016 |
Authors | Ong, P., Athanasiadis A., & Sechtem U. |
Journal | Cardiovasc Drugs Ther |
Volume | 30 |
Issue | 4 |
Pagination | 351-356 |
Date Published | 2016 Aug |
ISSN | 1573-7241 |
Λέξεις κλειδιά | Angina Pectoris, Cardiovascular Agents, Coronary Circulation, Coronary Vessels, Humans, Microvessels |
Abstract | Treatment of angina pectoris associated with coronary microvascular dysfunction is challenging as the underlying mechanisms are often diverse and overlapping. Patients with type 1 coronary microvascular dysfunction (i.e. absence of epicardial coronary artery disease and myocardial disease) should receive strict control of their cardiovascular risk factors and thus receive statins and ACE-inhibitors in most cases. Antianginal medication consists of ß-blockers and/or calcium channel blockers. Second line drugs are ranolazine and nicorandil with limited evidence. Despite individually titrated combinations of these drugs up to 30 % of patients have refractory angina. Rho-kinase inhibitors and endothelin-receptor antagonists represent potential drugs that may prove useful in these patients in the future. |
DOI | 10.1007/s10557-016-6676-z |
Alternate Journal | Cardiovasc Drugs Ther |
PubMed ID | 27358172 |